Dossier · GBTG · Dormant
GBTG · Global Business Travel Group, Inc.
Last analysed ·
Current thesis
Signed take-private: Long Lake buys Amex GBT at $9.50/share cash (~$6.3B), close 2H 2026, 69% of holders locked via voting agreements. Stock pinned under $9.50 pure merger-arb, ~1.7% capped upside vs ~36% deal-break tail. No momentum leg; not the setup.
Invalidation trigger
As long-arb, breaks on an 8-K terminating/revising the $9.50 Long Lake merger, a regulatory block, or price losing $8.50 (rising break odds → revert toward pre-deal ~$5.94, −36%). Already invalid as momentum: price capped at $9.50.
Thesis status
Open commitment scored if the trigger above fires How this is scored →Current Thesis
GBTG stopped being a narrative on 2026-05-04, when Long Lake Management (General Catalyst + Alpha Wave backed) agreed to take Amex GBT private at $9.50/share cash, ~$6.3B equity value a 60.2% premium to the 2026-05-01 close of $5.93. The stock gapped ~+57% and now sits pinned just under the cash cap. The preliminary merger proxy (PREM14A, filed 2026-05-28) confirms a vanilla path to close: majority-of-outstanding vote, already locked by 69% of shares (Amex, Expedia, Qatar Investment Authority, BlackRock) via voting agreements; close guided to 2H 2026; outside date 2026-11-02, extendable to 2027-02-02 for regulatory clearance. What remains is ~1.7% of arb spread against a ~36% deal-break tail. For a momentum book this is a clear pass the payoff is fixed and the ceiling is contractual.
Bull Case
- Vote is effectively pre-decided. PREM14A (2026-05-28) requires a majority of outstanding shares; the 69% lock-up via Amex/Expedia/QIA/BlackRock voting agreements clears that threshold before public holders vote. The special-meeting outcome is a formality.
- No financing condition. Per the 2026-05-04 announcement and PREM14A, the deal carries no financing out Long Lake has committed equity from General Catalyst and Alpha Wave, removing the most common LBO failure mode.
- Capped spread is real cash. From ~$9.3 to the $9.50 terms = ~1.7% gross. Over a ~6-month close window that annualizes to a low-single-digit cash substitute positive, but not alpha.
- Underlying franchise still growing into close. Q1 2026 (reported 2026-05-04): revenue $840M, +35% YoY, beating the $816M estimate; adj. EBITDA $150M; New Wins value $3.4B; 96% customer retention. A healthy target lowers the odds the buyer walks.
- Asymmetric break fees favor close. PREM14A sets a $270M parent reverse-termination fee vs a $200M company breakup fee the buyer is more penalized for walking than the target, a structural tilt toward completion.
Bear Case
- Inverted asymmetry is the whole story. Upside hard-capped at $9.50 (~1.7%); a break reverts to the pre-deal $5.93 (2026-05-01 close), roughly −36% from current levels. A momentum book never buys +1.7% / −36%.
- Regulatory/timing tail is open-ended. Close is only "2H 2026," with the outside date stretching to 2027-02-02 if approvals lag. A global corporate-travel data platform with a sovereign-wealth holder (QIA) invites extended antitrust/foreign-investment review; every month of drift erodes the already-thin annualized return.
- No re-rating path. The company suspended earnings calls and withdrew guidance (2026-05-04). There is no catalyst that lifts the stock above $9.50 the price is the deal terms, full stop.
- Sell-side already re-rated to deal-terms. 2026-05-05 (Benzinga): GBTG price target "lowered" analysts correctly treat it as an arb instrument, not a growth story. On broken-deal fundamentals it is not a clean value either: Q1 FCF swung to −$52M (from +$26M), net income $54M (−28% YoY), net debt $1.075B (2.0x).
- Superior-proposal odds are low. PREM14A has no go-shop; the board may entertain a Superior Proposal only with Parent matching rights, and the 69% lock-up makes a topping bid structurally hard. Positioning for a raised bid is a low-probability lottery, not a thesis.
Setup & Price Structure
- Price action: glued just below the $9.50 cash cap since the 2026-05-04 gap. The entire +57% move is in the rear-view; buying here is paying ~$9.3 to receive $9.50. There is no trend, so RSI/MA/EMA reads carry no information the tape trades the spread, not momentum.
- The ceiling is a contract number, not a price-discovery process.
- Liquidity/size: public market cap ~$3.1B; full deal equity value $6.3B across share classes. Liquidity is adequate but irrelevant there is nothing to size into.
- Verdict: structurally a flat merger-arb pin. Not tradable as momentum; occupies zero slots in a narrative book.
Catalyst Calendar (next 30 days)
- ~2026-06-18 (est.): Definitive merger proxy (DEFM14A) likely filed after SEC review of the 2026-05-28 PREM14A will populate the redacted record date and special-meeting date.
- ~2026-06-25 to ~2026-07-07 (est.): Special-meeting record date / virtual special-meeting date announcement; given the 69% lock-up, the vote is a non-event for price.
- Ongoing, no fixed date: Regulatory clearance progress (antitrust + foreign-investment review). The hard deadline is the 2026-11-02 outside date (→ 2027-02-02 if approvals slip) both outside the 30-day window.
- ~2026-08-06 (nominal): Next scheduled print but the company suspended calls and pulled guidance; expect no call and no tradable reaction.
What Would Change Our Mind
- A competing/raised bid above $9.50 disclosed via 8-K/13D the only event that re-opens upside. Low probability given the 69% lock-up and Parent matching rights, but it would convert this from a capped pin to a live event.
- Deal-break signal an 8-K terminating or revising the $9.50 merger, a regulatory block, or price losing $8.50 (rising break odds). A break reverts toward the pre-deal ~$5.94; that is a short/avoid condition, not a long entry.
- Re-rating to momentum would require the deal to die AND the underlying to re-accelerate revenue holding +30%+ YoY with a fresh AI-travel narrative and a clean breakout base. Absent both, there is no narrative leg to buy.
Correlation Notes
- Idiosyncratic by construction. As a signed-deal arb pin, GBTG decouples from beta it tracks deal probability and rate-of-close, not the consumer-discretionary or travel tape. SPY/XLY moves barely register.
- Theme membership is nominal. Tagged into "consumer-discretionary-rebound" by the discovery layer, but the price no longer responds to cyclical or travel-demand data; that linkage is dead until/unless the deal breaks.
- Peer read: other 2026 take-privates (the broader M&A-special-situations basket) share the same payoff shape thin capped spread, fat break tail. Useful as a regulatory-climate tell (a high-profile antitrust block elsewhere would widen this spread), not as a directional input.
Notes
- 2026-05-04: Long Lake Management (General Catalyst + Alpha Wave backed) to acquire Amex GBT at $9.50/share cash, ~$6.3B; stock +57% on announcement.
- Deal vote effectively locked: 69% of shares (Amex, Expedia, Qatar Investment Authority, BlackRock) signed voting agreements. Close guided 2H 2026, pending regulatory clearance.
- EARNINGS BLACKOUT N/A company SUSPENDED earnings calls and withdrew guidance pending merger (2026-05-04). Nominal next print ~2026-08-06 but expect no call.
- Q1 2026: revenue $840M (+35% YoY, beat $816M est); adj EBITDA $150M; net income $54M (-28% YoY); FCF -$52M; net debt $1.075B (2.0x); New Wins $3.4B, 96% retention.
- Deal-break downside reverts to pre-deal ~$5.94 ($9.50/1.60 premium); current ~$9.34 = ~1.7% capped upside. Inverted asymmetry do not occupy a momentum slot.
- Only bullish surprise = competing/raised bid >$9.50, but 69% lock-up makes that low-probability. Do not position ahead of it.
- 2026-05-04: Long Lake Management (General Catalyst + Alpha Wave backed) to acquire Amex GBT at $9.50/share cash, ~$6.3B equity value; 60.2% premium to 5/1 close of $5.93; stock +57% on announcement.
- Deal vote effectively locked: 69% of shares (Amex, Expedia, Qatar Investment Authority, BlackRock) signed voting agreements; requires majority of outstanding shares.
- PREM14A filed 2026-05-28: no financing condition; company breakup fee $200M, parent reverse-termination fee $270M; no go-shop (board may consider Superior Proposals with Parent matching rights). Record date / special-meeting date still redacted as of preliminary proxy.
- Outside termination date 2026-11-02, extendable to 2027-02-02 if regulatory approvals not obtained.
- EARNINGS BLACKOUT N/A company suspended earnings calls and withdrew guidance pending merger (2026-05-04). Nominal next print ~2026-08-06 but expect no call.
- Q1 2026: revenue $840M (+35% YoY, beat $816M); adj EBITDA $150M; net income $54M (-28% YoY); FCF -$52M; net debt $1.075B (2.0x); New Wins $3.4B, 96% retention.
- Deal-break downside reverts toward pre-deal ~$5.94 ($9.50/1.602 premium); current ~$9.3 = ~1.7% capped upside. Inverted asymmetry do not occupy a momentum slot.
- Only bullish surprise = competing/raised bid >$9.50, but 69% lock-up + matching rights make it low-probability. Do not position ahead of it.
Related · shared themes
AVNS
Avanos Medical, Inc.
All-cash $25.00/share take-private by American Industrial Partners (announced 2026-04-14, EV $1.272B, no financing condition) converted AVNS into a merger-arb pin. Narrative is dead; tape sits a few percent under the cash floor until a 2H-2026 close. Nothing for a momentum book to trade only a deal-break or topping bid revives it.
CNTA
Centessa Pharmaceuticals plc
Closed deal, not a trade: Eli Lilly's definitive ~$6.3B-cash + up to $1.5B-CVR acquisition (announced 2026-03-31, ~40% premium) capped the orexin story at the bid. Stock pinned near the ~$40 cash value, PTs clustered $40–42, post-M&A downgrade cluster no momentum leg above the bid. Merger-arb dead money pending close; DEAD for narrative-momentum.
COCO
The Vita Coco Company, Inc.
Coconut-water category leader re-rated +130% off lows on a real Q1 FY26 blowout (+37% sales, EPS beat, FY guide raised), but that catalyst already fired. Stock now consolidates ~7% below its $79.70 ATH with no binary for ~8 weeks until Q2 ~7/29. MATURING, not accelerating the edge is the 20-EMA pullback, not a chase at $74 near the high.
ESPR
Esperion Therapeutics, Inc.
Take-private kills the momentum trade: ARCHIMED $3.16/sh cash + CVR (announced 2026-05-01, close Q3-2026) pins the stock at the deal price. Last ~$3.14 = ~0.6% arb spread to cash plus a near-free CVR fixed-income-shaped, not narrative velocity. Theme DEAD for momentum; no leg to ride. Pass.